The Administrative Core plays a key role in the overall success of this CORT. The main goal of the Administrative Core is to foster a scientific environment that promotes the overall CORT objectives: to advance the understanding of systemic sclerosis (SSc) pathogenesis and to discover novel therapies for patients with SSc. Dr. Robert Lafyatis will lead the CORT and chair the Executive Committee, composed of the principal investigators of each of the projects and cores. Dr. Lafyatis has extensive administrative experience in leading program projects, study sections, and international meetings. He also has clinical and scientific experience in all of the scientific areas to be studied by CORT investigators. Dr. Rama Mallampalli, CORT Associate Director, Dr. Harrison Farber, Boston University Site Director and Dr. Michael Whitfield, Dartmouth Medical Center Site Director will assist Drs. Lafyatis in leading the CORT. Dr. Mallampalli has extensive experience in translational investigation into pulmonary disease and broad administrative experience that includes leading one of the largest pulmonary sections in the country. Dr. Farber is known internationally for his work on pulmonary arterial hypertension associated with SSc, and Dr. Whitfield in bioinformatics and systems biology. The administrative core will organize monthly Executive Committee meetings that will serve both as a time to discuss any administrative problems, but more importantly as a time for scientific exchange between investigators. It will assemble a highly-experienced Advisory Committee composed of physician-scientists, working in the fields of SSc skin disease, interstitial lung disease, pulmonary arterial hypertension, biomarkers and clinical outcomes. The Administrative Core committee will organize annual review by the Advisory Committee to critique progress, probe obstacles, and provide advice for new scientific directions. The CORT Administrative Core will manage budgets, assist the director in preparing reports, manage the website, supervise trainess, and arrange enrichment seminars. The Administrative Core will serve eight basic functions: 1) Provide leadership for individual project and cores, and encourage cooperation and collaboration between projects and cores; 2) Provide day-to-day scientific oversight of the program as a whole by maintaining communication with and among project and core investigators; 3) Ensure communication and coordination between the University of Pittsburgh with Boston University and the Dartmouth Site Investigators; 4) Provide mechanisms for external oversight and review for the program project; 5) Provide administrative support for the program including personnel, financial and other management functions; 6) Assess the scientific merit and programmatic value of Pilot and Feasibility Projects and make recommendations for submission to the NIAMS; 7) Provide enrichment opportunities for investigators, and 8) Organize mentoring for young investigators. Through these activities the Administrative Core will provide key support and coordination for all CORT functions.

National Institute of Health (NIH)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZAR1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Stifano, Giuseppina; Sornasse, Thierry; Rice, Lisa M et al. (2018) Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. Arthritis Rheumatol 70:912-919
Franks, Jennifer M; Cai, Guoshuai; Whitfield, Michael L (2018) Feature specific quantile normalization enables cross-platform classification of molecular subtypes using gene expression data. Bioinformatics 34:1868-1874
Apostolidis, Sokratis A; Stifano, Giuseppina; Tabib, Tracy et al. (2018) Single Cell RNA Sequencing Identifies HSPG2 and APLNR as Markers of Endothelial Cell Injury in Systemic Sclerosis Skin. Front Immunol 9:2191
Fleury, Michelle; Belkina, Anna C; Proctor, Elizabeth A et al. (2018) Increased Expression and Modulated Regulatory Activity of Coinhibitory Receptors PD-1, TIGIT, and TIM-3 in Lymphocytes From Patients With Systemic Sclerosis. Arthritis Rheumatol 70:566-577
Moll, Matthew; Christmann, Romy B; Zhang, Yuqing et al. (2018) Patients with systemic sclerosis-associated pulmonary arterial hypertension express a genomic signature distinct from patients with interstitial lung disease. J Scleroderma Relat Disord 3:242-248
Meiners, Silke; Evankovich, John; Mallampalli, Rama K (2018) The ubiquitin proteasome system as a potential therapeutic target for systemic sclerosis. Transl Res 198:17-28
Rice, Lisa M; Mantero, Julio C; Stratton, Eric A et al. (2018) Serum biomarker for diagnostic evaluation of pulmonary arterial hypertension in systemic sclerosis. Arthritis Res Ther 20:185
Goswami, Rishov; Cohen, Jonathan; Sharma, Shweta et al. (2017) TRPV4 ION Channel Is Associated with Scleroderma. J Invest Dermatol 137:962-965
Cheong, Fei-Ying; Gower, Adam C; Farber, Harrison W (2017) Changes in gene expression profiles in patients with pulmonary arterial hypertension associated with scleroderma treated with tadalafil. Semin Arthritis Rheum 46:465-472
Yamashita, Takashi; Asano, Yoshihide; Taniguchi, Takashi et al. (2017) Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis. J Invest Dermatol 137:631-640

Showing the most recent 10 out of 70 publications